ABSTRACf. We measured neonatal apo A-I and apo B by ELISA, and apo(a) by RIA, in capillary blood spotted onto filter paper in samples also used for routine neonatal screening in 1032 consecutively born babies. In the 2-to 5-d-old babies with birth weights~2.0 kg (n = 919), mean ± SD levels of apo A-I and B were 0,48 ± 0.19 g/L and 0.24 ± 0.14 g/L of whole blood, respectively. The apo A-I levels were affected by birth weight (negatively) and by age at sampling (positively). The apo B levels were affected positively by both variables, and girls had higher levels than boys (p < 0.01). These variables accounted for 3.5 and 6.2% of apo A-I and apo B variability, respectively (p < 0.001). The apo(a) levels (mean ± SD, 20 ± 23 U/L; median, 14 U/L, n =1032) were unaffected by these factors. After adjustment for these variables, apo A-I levels were nearly normally distributed, whereas those of apo B were still positively skewed. The apo(a) distribution was strongly positively skewed and 1.2% of babies had levels above the equivalent of 25 mg/dL of lipoprotein(a) in serum. Our study shows that blood spots can be used to estimate apo A-I, apo B, and apo(a) levels in neonates, and establishes normal ranges. The results suggest that the apo(a) gene is expre ssed during the 1st postnatal week and that levels are independent of birth weight and apo A-I and B concentrations. They also define the effects of birth weight and age at sampling on neonatal apo A-I and B levels. (Pediatr Res 28: 496-501, 1990) Abbreviations Lp(a), Iipoprotein(a) Carefully conducted studies over the past decades have demonstrated conclusively that atherogenesis begins in childh ood (I). In cross-sectional studies, Stary (2) has documented a change from fatty streaks in infan cy to fibrous plaques in youn g adulthood. In longitudinal studies, Berenson et al. (3) have elegantly described the changing lipid profile from infancy to adolescence and young adulthood. The y also showed in young adults who died sudd en accidental deaths a high correlation between antemortem LDL cholesterol levels and the extent of surface involvement of the aorta with fatty streaks (3); lesions in coronary arterie s were inversely related to HDL cholesterol concentr ations. There is now increasing evidence that high levels of apo B, the carrier protein for the ath erogenic LDL, and low levels of apo A-I, the prin cipal carrier protein for the protecti ve HDL , are
< 0.001). The apo(a) levels (mean ± SD, 20 ± 23 U/L; median, 14 U/L, n =1032) were unaffected by these factors. After adjustment for these variables, apo A-I levels were nearly normally distributed, whereas those of apo B were still positively skewed. The apo(a) distribution was strongly positively skewed and 1.2% of babies had levels above the equivalent of 25 mg/dL of lipoprotein(a) in serum. Our study shows that blood spots can be used to estimate apo A-I, apo B, and apo(a) levels in neonates, and establishes normal ranges. The results suggest that the apo(a) gene is expre ssed during the 1st postnatal week and that levels are independent of birth weight and apo A-I and B concentrations. They also define the effects of birth weight and age at sampling on neonatal apo A-I and B levels. Carefully conducted studies over the past decades have demonstrated conclusively that atherogenesis begins in childh ood (I). In cross-sectional studies, Stary (2) has documented a change from fatty streaks in infan cy to fibrous plaques in youn g adulthood. In longitudinal studies, Berenson et al. (3) have elegantly described the changing lipid profile from infancy to adolescence and young adulthood. The y also showed in young adults who died sudd en accidental deaths a high correlation between antemortem LDL cholesterol levels and the extent of surface involvement of the aorta with fatty streaks (3); lesions in coronary arterie s were inversely related to HDL cholesterol concentr ations. There is now increasing evidence that high levels of apo B, the carrier protein for the ath erogenic LDL, and low levels of apo A-I, the prin cipal carrier protein for the protecti ve HDL , are more predictive of cardiovascular risk than their respective lipoproteins (4) .
Lp(a) is another lipoprotein for which high levels are independently associated with enhanced risk (5) (6) (7) . Lp(a) particles are found in atheromatous plaque s along with LDL (8, 9) . The Lp(a) particle conta ins apo(a) disulfide bound to apo B, but is immunochemicall y distinct from LDL. The plasma concentration of Lp(a) in adults has a wide range, and is believed to be regulated by a series of codominant alleles for apo(a) at a single locus ( 10) .
Recent clear docum entation of the reduced cardiovascular risk associated with lowering elevated LDL cholesterol (II-IS) has led to recommendations for population-based cholesterol measurements in adults (16) (17) (18) (19) . If children with a dominantly inherited disorder of lipid metabolism such as familial hypercholesterolemia and familial combined hyperlipoproteinemia could be identified before the occurrence of a premature vascular event in one of their parents, early intervent ion could be made available to the whole family.
For children, general screening of cholesterol is a controversial issue. Current recommend ation s of the Committee on Nutrition of the American Academy of Pediatrics are for cholesterol measurements onl y in children with a family history of prem ature cardio vascular disease (20) . However, this approach has been recently shown to have a low sensitivity, and there are differing views on the strategy that should eventually be adopted (21) .
Denni son et at. (22) found that only 40% of the white children and 21% of the black children with elevated LDL cholesterol levels had a parental history of vascular disease. For community acceptance, screening procedures must provide accurate information and preferably identify a range of potenti al disorders in addition to being minimally intrusive. Our earlier studies explored screening for apo B only (23) . The approach of our present stud y was to measure levels of apo A-I and apo(a) in addition to apo B in neonatal blood spots that are already available for screening for phen ylketonu ria and other inborn errors of metab olism.
MA T ERIALS AND METHODS
We studied 1032 neonates born consecutively between Ma y and September 1989 at the Royal Hospital for Wom en in Sydney. At that hospital , a heel-prick blood sample was collected ont o filter paper (newborn screening cards prepared from filter paper SS 2992, Schleicher and Schuell , Keen e, NH) from each neonate, usually on d 3-5 after birth , as part of the New South Wales Department of Health neonatal screening program for phen ylketonuria, hypoth yroidism, cystic fibrosis, and galactosemia. Th e sam pies were air-dried and stored at -20·C for 24 h and thereafter at -70T in our laboratory unt il assay. Levels of apo(a), A-I, and B were then measured within 2 wk of collection. The proto col was approved by the Ethics Committee of the University of New South Wales.
Neonates. The mean age ± SD of these 1032 neonates on the [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . However, most sampies (77%) were collected 4 or 5 d after birth and only 5% of the neonates were sam pled either before d 2 or after d 7. Th e mean ± SO birth weight of the 1032 neonates was 3.29 ± 0.64 kg, (range 0.6-4.9 kg). In 86% of the neon ates, birth weights were 2.0 to 4.0 kg; only five neonat es weighed less th an 1.0 kg at birth , 3.5% of all neonate s were between 1.0 and 2.0 kg, and 9.9% were above 4.0 kg. Neonates whose birth weights were below 1.0 kg tend ed to be sampled on later days after birth , and neonates with birth weights above 4.0 kg tended to be sampled early (Table I) . When least squares linear regression analysis was used to assess birth weight and age at samplin g, the correlati on coefficient was 0.135 (p < 0.000 I).
Th ere were 512 girls and 520 boys. The mean age at sampling was 4.2 d for both girls and boys. As expected, the mean ± SO birth weight in girls (3.22 ± 0.62 kg) was significantl y lower than that in boys (3.35 ± 0.64 kg; p < 0.0001). After excluding 113 low-birth-weight and late-sampled neonates (see Results), th ere were 450 girls and 469 boys. The mean ± SO birth weight for girls (3.304 ± 0.486 kg) was still significantly lower than that for boys (3.370 ± 0.503 kg; p < 0.001). The mean age remained the same, 4.2 d for both girls and boys.
Parents were inform ed of the study, which was approved by the Ethics Committee of the University of New South Wales, and none declined to have their baby's samples tested .
apo A-I and apo B assays. We measured blood spot apo A-I and apo B levels by ELISA as described by us previously (24, 25) . Calibration apolipoprotein serum (Boehringer-Mannheim, Mannheim, F.R.G .), which we mad e up in the form of dried blood spots, was used for the calibration curve. Quality control blood spots for each assay were prep ared from lyophilized pooled serum provided by the Center for Disease Control (CDC, Atlanta, GA) and control seru m (Behring Diagnostics, Behringwerke AG, Marburg, F.R.G.). All reported apo A-I and apo B levels were dete rm ined using CDC apo A-I and apo B reference material (CDC 1883) as primary standards. Only one batch of calibrati on and quality control dried blood spots was prepared and used throughout the study. T he dried blood spots were stored at -70°C in sealed plastic bags unt il assayed.
For the validation of the dried blood spot apo A-I assay, we measured apo A-I levels of simultaneously collected finger-prick blood spotted onto filter paper, venous blood spots, and venous sera from 20 adult subjects. The apo B levels of simultaneously collected venous blood spots and sera from II subjects were also determined to assess the validity of the dried blood spot apo B assay. We have previously shown a close correla tion between simultaneously obtained capillary and venous blood spot apo B levels (26) . All samples were stored at -70°C before assay.
apo(a) assay. To measure dried blood spot apo(a) levels, we modified an RIA serum assay for apo (a) (Pharmacia Diagnostics 
AB, Upp sala, Sweden) as follows. Three 3-mm diameter blood discs were cut from each dried blood sample and transferred to a polystyrene test tube. Twenty ILL of Tween-20 buffer (5 g/L Tween-20 in PBS, pH 7.4) were then added to the discs to facilitate the elution of apo(a). After incubation for an hour, 20 ILL of pretreatment buffer (Pharmacia Diagnostics) was added to the soaked discs, which were then incubated for another hour to pretre at the apo(a) in the eluate. The pretreated eluate was then diluted by 60 ILL of diluent (Pharmacia Diagnosti cs) and transferred to a fresh tub e to react with antibody solution. Th e antibody solution was prepared by mixing an equal volume of 12sI_labeled monoclonal anti-apo(a) antibody solution with anoth er unlabeled monoclonal anti-apo (a) antibody solution. These two MAb bind to different epitopes on the apo(a) molecule (27) . The reaction was carried out at room temperature for I h. The ant igen-antibody complexes were then precipitated by precipitat ion buffer (Pharmacia Diagnostics). The precipitin was separated from the supernatant by centrifugation, and the radioactivity of the precipitin was counted by gamma counter.
Th e blood spot apo(a) concentrations were read off the linearlogarithmic dried blood spot calibration curve. The calibration dried blood spots ( 16-8 15 U/L) were manufactured by diluting pooled apo(a) serum solut ions with 5% BSA in PBS containing PBS-washed fresh human red blood cells. These standard mixtures were then pipetted onto filter pap er and air-dried before they were stored at -70°C. Th e apo (a) concentration of the pooled seru m was determ ined in four separate seru m apo(a) assays in quadruplicate in each assay, and expressed in Pharmacia un its, i.e. UI L, which is equivalent to mg/L, Aliquots of each of two apo(a) control serum soluti ons included in the Pharmacia serum RIA kit were mixed with equal volumes of fresh human blood red cells and used to prepare quality control dried blood spots. Th e apo (a) levels of these two control blood spots were 336 ± 23 and 103 ± 6 U/ L of whole blood, calculated from Pharmacia produ ct inform ation . Onl y one batch of calibration and control dried blood spots was prepared and used throughout the study. The calibration and control spots were treat ed and assayed in exactly the same way as the sample spots. The mean ± SO within-assay coefficient of variation was 4.1 ± 0.3%, which was obtained from 40 blood spot samples assayed in duplicate with apo(a) con centrations ranging from 10 to 512 U /L of whole blood. Between-assay variations were monitored by assaying control blood spot samples in each assay of a tot al of 10 assays. The between-assay coefficient of variation was 4.7% for th e control at 336 U / L of apo(a) and 4.3% for the contro l at 103 U/ L of apo(a).
To determine whether the dried blood spot apo(a) level reflects accuratel y the corresponding serum apo(a) level, we assayed apo(a) concentrations in 39 simultaneously collected venous dried blood spot and venous serum sampl es. These samples were collected from children and adults aged from 2 mo to 65 y. All samples were stored at -70OC before the assay.
R elationship between apolipoprotei n levels and other variables. Because our earlier studie s had shown that neon atal apo B levels were affected by birth weight, age at sampling, and sex, we assessed the effects of these variables on the levels of th e thre e apolipoprotein s measured.
S tatistics. Th e mean (± SO) and median levels were calculated for each variable measured in the 1032 babies. Skewness and kurtosis were calculated to assess the normality of the frequency distributi ons of th e apolip oprotein levels and the appropriateness of statistical meth ods for comparisons. Th e t test after log transformation was used for comparison of apo(a) and apo B levels in different age, sex, and birth weight group s. Th e t test was used for the comparison of apo A-I levels, in relation to birth weight, sex, and age of sampling. Analysis of variance (F test) was also used in the comparison of these variables among the subgroups.
To quantitate the effects of the independent baby-related variables, we assessed age at sampling, birth weight, and sex by partial multiple linear regression anal ysis with apo(a), apo A-I, and apo B as dependent variables. Th e percent variatio n in each of the dependent variables, apo(a) , A-I, and B, that could be attributed to each inde pendent variable was obtai ned by dete rm ining the squa re of the multiple regression coefficient R and multiplying th is by 100. To adjust each indi vidual baby's measured apo A-I and B values for the effects of birth weight, sex, and age at sampling, we calculated a "residual" value for apo A-I and B for each baby and added this to th e apo A-I and B population means. The residua ls were obtained by subtracting expected levels of the dependen t variables apo A-I and B from thei r actual measured values. The expected levels, in turn, were calculated by multi ple regression equ ation s, incorporating the indepe nden t variables birth weight, sex, and age at sam pling (see Results). 
RES ULTS
Validation of dried blood spot apoia), A-I, and B assays. Apolipoprotein levels measured in dried blood spots reflected accurately the corresponding seru m levels. T he correlation coefficients for apo(a), apo A-I, and apo B were 0.97, 0.90, and 0.89, respectively, and this is shown for apo(a) in Figure I . The fingerprick capillary dried blood spot apo A-I levels were also highly associated with both venous dried blood spot (r = 0.9 1; P < 0.0001) and veno us serum apo A-I levels (r = 0.90; p < 0.000 I).
Th ese findings, togeth er with our earlier ones for apo B (26), estab lish that capillary blood spotted onto filter paper can be used for the estim ation of venous blood apolipoprotein levels.
Frequency distrib utions of apo(a), A -I, and B.
The frequency distribution of blood apo(a) levels obt ained from all 1032 neonates tested is shown in Figure 2 . This is very positively skewed, with a high prop ortion of neonates (25%) having no detectable apo(a) in their dried blood spot samp les. Th e mean ± SO apo(a) blood level was 20 ± 23 U/ L of whole blood. The median apo (a) value was 14 UIL. In cont rast, after the correction of babyrelated factors and excludin g 113 premature neonates the distributi on of blood apo A-I levels was almo st normal in these 919 neonates (Fig. 3) . The mean blood apo A-I level ± SD was 0.48 ± 0.19 g/ L of whole blood , and the median level was 0.45 g/ L, T he frequency distribution of the "corrected" blood spot apo B levels in these 919 neon ates is shown in Figure 4 , and was more positively skewed than that for blood apo A-I levels. The mean blood apo B level ± SO was 0.24 ± 0.14 g/L of whole blood and the median level was 0.20 g/L, All neonates had measurable blood apo B values from their dried blood spot sampl es. When we assessed the distributi on of apo B/ apo A-I ratios, the pattern was also highly positively skewed (Fig. 5) . The mean ± SO apo B/ap o A-I ratio was 0.59 ± 0.48, and the medi an was 0.46 . But none of these distribut ion s was skewed as much as was th e distribution of blood apo(a) levels. Th e frequency distribu tion of blood apo(a) levels in th ese 919 neonates was in the same pattern as that for the 1032 neon ates (Fig. 2) . S ex differences. The mean apo(a) levels for girls (n = 5 12) and boys (n = 520) were the same at 20 ± 23 U/ L of whole blood. T he median apo(a) level in girls (15 UI L) was 2 UI L higher than that in boys (13 UI L), but the difference was not statis tically significant. The mean apo A-I level ± SD of 0.49 ± 0.19 g/ L in girls (n = 450) was 4% higher than that in boys (0.47 ± 0.18 g/L , n = 469) but not significa ntly so by both t test and F test.
Comparison of med ian s between girls (0.46 g/ L) and boys (0.44 g/ L) also did not show a significant difference by non param etric testing. However, blood apo B levels in girls (n = 459) were significantly higher than in boys ( n = 469; p < 0.01), and this was con sistently so in each birth weight group (Fig. 6) . The median levels in girls (0. 
Ta ble 2. Birth wt compared with neonata l apo(a), apo A-I, and apo B levels, ratio of apo BIA-I, and age at sampling"
* Sa mpling tended to be delayed in ba bies with birth wt under 2.0 kg.
Results presented as mean ± SO . boys (0.57 ± 0.43, n = 469), and the difference was not statistically significant. Th e median ratios in girls and boys were 0.47 and 0.44, respectively.
Influ ence of birth weight and day of sam pling of apo(a), A-I, and B levels.
Blood apo(a) levels of all 1032 babies were not systematically influenced by birth weight (T able 2) or day of sampling (Ta ble I), or by both of these variables togeth er. Linear regression analysis with apo(a) level as the depend ent variable and birth weight and day of sampling as independent variables either separately or together showed that R 2 between apo(a) and age was 0.0002, between apo(a) and birth weight was 0.006, and between apo(a) and birth weight and age was 0.006.
By contrast, apo A-I levels were clearly affected by both da y of sampling and birth weight. When apo A-I levels were regressed on birth weight and day of sampling separa tely as shown in Tabl e I, apo A-I levels were positively associated with the day of sampling (r = 0.17, n = 1032, p < 0.000 I) with R 2 at 0.029 , but as shown in Table I , negatively correlated with birth weight (r = -0.11, n = 1032, P < 0.00 1) with R 2 at 0.012. Using partial multiple regression analysis, these two independen t variables still significantly influenced apo A-I levels with multi-R' at 0.04 1 (n = 1032, p < 0.00 I). Thus, birth weight and day of sampling together contributed 4.1% of the variability of blood apo A-I levels; birth weight accounted for 1.2% and day of sampling, 2.9%.
Blood apo B levels of these 1032 neonates were positively associated with both birth weight ( Table 2 ) and day of sampl ing (Ta ble I). Thi s association was also significant when both of the variables were considered together. Th e partial multiple regression analysis indi cated that birth weight and day of sampling contributed 4.8% of the variability in apo B levels with birth weight accounting for 4.0% and day of sampling 0.8% (n = 1032).
Adjusted individu al apo A -I and apo B levels. Because blood apo A-I and B levels were clearly influen ced by both birth weight and day of sampling, we contro lled for these variables to facilitate direct comparisons between babies. Th ere was no need to adjust indi vidual apo(a) level for th ese two independent variables, inasmuch as we had not found any significant associations.
When considering the birth weight and day of sampling data for all 1032 neon ates shown in Table I , it is app arent that there are two popu lation s, those sampl ed on d 2 to 5 and th ose sampled later. Th e latter group cont ain ed largely premature babies and infants with an abn ormal postnatal course. Because apo A-I and apo B levels were significantly affected by birth weight and age at sampling, to minimize confoundin g effects from th is relatively small subset we confined our analysis of apo A-I and apo B to neonates whose birth weights were above 2.0 kg and whose blood spot samples were taken on d 2 to 5 inclusive after birth . Th ere were 919 neonates who satisfied these criteria. Levels of apo A-I or apo B as dependent variables were regressed on birth weight, day of samp ling, and sex as independent variables by parti al multiple regression analysis. Fem ale sex was counted as I and m ale as 2. In these 919 babies, apo A-I levels were still influenced by birth weight and day of sampling, and these variables accounted for 3.5% of ap o A-I variability. T he apo B levels were also affected by all three ind ependent varia bles, and they acco unted for 6.2% of the variability in blood apo B levels. The apo A-I level of each individual neonate was adju sted by th e regression equation: From these "expected" levels, a "residual" value was obtained by subtracting the expected value from the measured value (see Materials and Methods). Clustering ofapolipoprotein levels. After adjusting the individual apo A-I and ap o B levels for th e bab y-related varia bles, th e cut-off point for th e bottom 5% of the distribution of apo A-I was 0.21 gj L of whole blood and for the top 5% of apo B levels, 0.4 6 gj L; th e 95th percentile for th e dist ribution of th e apo B to A-I ratio was 1.3. For apo(a), the 95th percentile was 59 UjL of whole blood.
When neon ates in the top 5% of the apo B to A-I ratio were assessed, 32% of th ese babies had apo A-I levels in the bottom 5% of th e ap o A-I distribution, an d 33% had apo B levels abo ve th e 95th percentile of the apo B distribution. By contrast, onl y 4.2% of neonates in th is apo B to A-I ratio subpopulation had apo(a) levels above the 95th percent ile of 59 U jL of whole blood . This apo(a) subset appe ared in 5.7% of th e top 5% of the apo B distribution and in 5.3 % of the bottom 5% of the apo A-I d istribution. We concluded that, whereas there appe ared to be an associati on between high apo B and low apo A-I levels, ap o(a) concentrations were not related to th ose of either of th ese ap olipopr oteins.
DISCUSSION
Our present stud y extends our earlier studies, which were confined to neonatal apo B (23) , by providing a profile during the first few days after birth of the major apolipoproteins shown to be associated with enhan ced cardiovascular risk. It shows that th ese apol ipoproteins can be measured accurately in a drop of blood spotted onto filter paper for easy collection and storage, and that a large number of samples can be proces sed convenientl y and econom ically. Whereas we (24) (25) (26) and others (28) (29) (30) have already established that apo A-I and B can be measured in the dried blood spot sample by both ELISA and radial immunodiffusion methods, as far as we are aware apo(a) has not previously been estima ted in these sam ples. Th e RIA we used for apo(a) in dried blood spots reflected accurately venous serum levels (Fig. I) ; likewise, ELISA measurement s of blood spot apo A-I and B levels accur ately reflected venous seru m levels and levels obtained by radial im m unodiffusion, th e standard meth od for our laboratory at th at time.
The striking feature of the distribution of apo(a) in the neonatal period is its close resemblance to th at found in adult Caucasian populations. We found it to be markedl y skewed; about 25% of bab ies had levels either very low or not detectabl e, whereas a small prop orti on (1.2%) had levels that in adult populations are associated with enhanced cardi ovascular risk, i.e. levels mo re th an 12.5 mgjdL in whole blood equivalent to m ore than 25 mgjdL in seru m . Furthermore, neonatal apo(a) con centrations were unrelated to sex, birth weight or age at sampling. These results are all consistent with pred ominant genetic regulation of apo(a) levels and establish that the apo(a) gene can be fully exp ressed by th e 1st 2 to 5 postn atal da ys. Labeur et al. (3 I) have reported a trend toward an increase in serum levels from d 0 to 7 and a further increase to 180 d postpartum. This was not evident between d 2 and 7 in our series, and a longitudinal study would be required to establish whether or not a trend does occur. It is noteworthy, too, that neon atal apo(a) conc entrations were quite independent of those for apo B and A-I.
In contrast to apo(a), ap o A-I con centrations were affected by birth weight (negatively) and age at sampling (positively) but were not different for boys and girls. These two variables, birth weight and age at sampling, could account for only 4.1 % of the total varia bility of blood apo A-I levels for the whole series ( n = 1032) and 3.5% for the 919 neonates weighing 2.0 kg or greater at birth and sampl ed when 2 to 5 d of age. Th e distribution of apo A-I was very close to norm al. Storage at -20°C for the first 24 h afte r collection and th en at -70°C and analysis within 2 wk obviated an y confounding effects of storage th at can falsely elevate measured apo A-I levels, probably due to oxidation (32) .
For apo B also, th e possible confounding effects of diminished immunoreactivit y with storage at room temperature were obviated. However, in genera l, the results obtained with th e ELISA method mirrored closely th ose we have pre viously report ed for apo B using th e more labor intensive radial immunodiffusion approac h (23) . Levels were significantly higher in girls, and posit ively related to birth weight and age at sampling in both sexes. Together the se three variables accounted for 4.8 % of the variability; birth weight accounted for 4% (n = 1032). For babies sampled on d 2 to 5 and with birth weights of 2.0 kg or greater, these three variables acco unted for 6.2% of th e variability. Age at sampling had only a small effect (0.8%), suggesting that apo B levels are largely stabilized by the 3rd to 5th postnatal day. After cor recting for th ese varia bles, th e distribution of apo B levels was strongly skewed, as was found in our earlier study (23) , and differed m arkedl y fro m that ofapo A-I. Although both genetic and perinatal factors could be contributing to this difference, there is the possibility of greater variability of apo B gene expression in the Ist week of life. Our earlier follow-up stud ies of neonates with high levels and their parents would also be consistent with a genetic explanation (33) .
Th e use of computer-determined adju sted values for ap o B to establish a cut-off point for recall of infants with high values and their parents should provide a higher yield of genetically determined apo B elevation at retesting. Also, by confining our analysis and recall to babies of birth weight great er than 2.0 kg sampled on d 2 to 5, we sho uld be assessing a population mu ch closer to th at seen in th e general community. Our University maternity hospital is a terti ary referral center with a much higher than average proportion of complicated pregnancies and births and underweight and sick babies, who are usuall y sampled later than d 5.
After correcting for the variables affecting apo B and apo A-I, the distribution of th e apo Bj apo A-I ratios was also markedly skewed and appe ared to come from two separate population s. Separation was evident before correcting for th e bab y-related variables but was mo re evident after corre ction (Fig. 5) . Bab ies could be separated on th e basis of the distribution of apo B alon e, but th ose with high apo Bj apo A-I ratios were more clearl y separated from th e rest of th e population . Th ere was, furthermore, some clustering in that approximately 113 of those babies who con stituted th e top 5% of the rati o of apo Bjapo A-I also appeared in the top 5% of the adjusted apo B distribution; 1 13 also appeared in th e lower-most 5% of the adjusted apo A-I distribution . Int erestingly, th e ratio for boys and girls was not different. This result is at variance with the higher rati o we reported in boys based on measurement s in just 57 neonates (25) . Thi s emphasizes the fact that when many variabl es are influencing neonates, observations in a large number of infants are required before valid con clusions can be drawn. Because the ap o Bj apo A-I rat io is reportedly a sensitive predictor of cardiovascular risk (34) (35) (36) (37) (38) , it is of consi derable interest to see whether In summary, we have developed simple, inexpensive assays for apo B, apo A-I, and apo(a) levels in dried blood spots on filter paper, and used them to describe the differing distribution patt erns of these apolipoprote ins among 1032 consecutively-born neonates; we have also identified some of the variables affecting levels and quantified their concentrations. By taking account of these variables we have calculated corrected apo B and A-I values with a view to developing arbitrary cut-off points for recall of those with high apo B levels and apo Blapo A-I ratios. We have also examined the distribution, amo ng these groupings, of apo(a) levels elevated above an arbitrary cut-off point used to predict increased coronary risk in adults, and shown that high levels are not correlated with either high apo B levels or with high apo Byapo A-I ratios in this neonatal population.
Th e inform ation gained expands knowledge of the behavior of these apolipoprotein s in the neonatal period and documents the extent of the expression of the apo(a) gene in the first few days ofl ife. The latter results are in accordance with the predominance of genetic regulation of apo(a). Appropriate follow-up of identified families should determ ine whether or not these data could be used to imp rove prospects for detecting families at enh anced cardiovascular risk.
